Category: St. Jude Medical
Google Ventures, the VC arm of the Silicon Valley tech monolith, pumped more than ⅓ of its venture spend into healthcare and life science startups during 2014.
Google (NSDQ:GOOG) took a bigger bet on healthcare in 2014, investing more than ⅓ of the its venture dollars in healthcare and life science interests, according to the company and published reports.
Here's a look at some of the top regulatory stories for medical device companies this week: Cianna Medical wins FDA nod for breast surgery device; St. Jude Medical wins CE Mark for Quadra Allure MP pacemaker; Medtronic wins FDA approval for more Attain Performa quad defib leads; FDA postpones panel meeting for VertiFlex's Superion spine device; Report: FDA doesn't disclose most adviser's ties to medtech
Here's a look at some of the top legal news stories for medical device companies this week: CardioKinetix raises $50m, inks buyout deal with Edwards Lifesciences; Angel Medical raises $10m for ischemia devices; Zyga Technology raises $2m; Image Stream Medical looks at $8m
St. Jude Medical says it won CE Mark approval in the European Union for its Quadra Allure MP pacemaker, claiming it as the sole cardiac resynchronization therapy pacemaker to offer multi-point pacing.
Angel Medical Systems, developer of ischemia monitoring devices, is halfway toward raising a planned $20.5 million debt offering.
Angel Medical Systems said it raised about half of a planned $20.5 million debt offering.
The New Jersey-based developer of implantable ischemia monitoring devices said in a regulatory filing that it has pulled in more than $10.2 million so far, with close to $10.29 million yet to be raised.
Spinal Modulation closes enrollment in a U.S. pivotal study of its Axium neurotransmitter system for the treatment of chronic pain.
Spinal Modulation said it completed enrollment in a U.S. pivotal study of its Axium neurotransmitter system for the treatment of chronic pain.
A long-term study of data from registries set up by St. Jude Medical for its Optim-insulated defibrillator leads shows that they're largely free of the externalized conductor problem that plagued their Riata predecessors.